Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Case-Based Peer Perspectives
Expert Perspective Virtual Tumor Board
Interviews
Investigator Perspectives
Precision Medicine
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | Upfront Therapy for mRCC

Specialties >>

Acute Myeloid Leukemia
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Gastric Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Gynecologic Cancers
Head and Neck Cancers
Hematology
Hepatocellular Carcinoma
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Myeloproliferative Neoplasms
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Skin Cancers
Soft Tissue Sarcoma
Thyroid Cancers

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

The Journal of Targeted Therapies in Cancer
March 2012

Clinical Articles

Full PDF Version of OncologyLive Targeted Therapy News from March 2012
Colorectal Tumor Marker: Molecular Evaluation Sheds Light on Negative Lymph Node Status
Changing Paradigms for NSCLC in Personalized Therapy Era
Biomarker Identifies Patients With Advanced Lung Cancer Who Will Gain Most From Add-On Cetuximab
Prostate Cancer Armamentarium Expanding
Emerging Biomarker Science Presents Practical Questions
PARP Inhibition Explored in Triple-Negative Breast Cancer
Clinicians Face Challenges Integrating New Therapeutics
Trial Shows Denosumab Delays Development of Bone Metastasis in Hormone-Resistant Prostate Cancer
New Assays Open Window in Evaluating Leukemia Types
Using Molecular Markers in AML for Prediction, Treatment, and Monitoring
Predictive Markers Needed for Adjuvant Chemotherapy
Hospitals for Vulnerable Patients Less Likely to Provide Optimal Lung Cancer Care
FDA Approves Axitinib for Advanced Kidney Cancer Patients
Two New Options Represent Breakthroughs
Hair Professionals Often Check Customers for Worrisome Skin Lesions
Better Communication of Complex Medical Information Needed
Some Follicular Lymphoma Patients May Benefit From Treatment Delay
The Hope and Challenges of Personalized Medicine
Targeted Therapies Trials in Progress
NICE’s Reluctance to Back Yervoy Turns on Cost-Benefit Perceptions
Pierre Hainaut, PhD: Awakening the “Guardian of the Genome”
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.